Supplementary Table 1 – Biomarker Summary Statistics By Any Acute Kidney Injury (atleast ≥
0.3mg/dL increase or a ≥ 50% rise of baseline serum creatinine)
All Patients (n=106)
No AKI (n=50)
Any AKI (n=56)
Wilcoxon
P value
Biomarker
Mean (SD) [Q1, Median, Q3]
Mean (SD) [Q1, Median, Q3]
Mean (SD) [Q1, Median, Q3]
IL-6 pre-op
4.1 (10) [0.6, 1.0, 2.8]
N=82
6.2 (14) [0.6, 1.7, 3.1]
N=38
2.4 (3.6) [0.6, 0.6, 2.5]
N=44
0.2
IL-6 day 1
128 (119) [52, 96, 165]
N=105
127 (113) [59, 92, 145]
N=49
129 (125) [46, 96, 176]
N=56
0.8
IL-6 day 3
70 (102) [19, 38, 74]
N=94
68 (108) [19, 38, 67]
N=43
72 (97) [19, 37, 83] N=51
0.9
IL-10 pre-op
2.1 (3.4) [0.9, 0.9, 0.9]
N=82
2.5 (4.0) [0.9, 0.9, 2.0]
N=38
1.7 (2.8) [0.9, 0.9, 0.9]
N=44
0.2
IL-10 day 1
135 (144) [61, 93, 139]
N=104
133 (153) [50, 87, 156]
N=49
137 (138) [65, 94, 122]
N=55
0.7
IL-10 day 3
3.1 (7.2) [0.9, 0.9, 2.5]
N=77
1.6 (2.1) [0.9, 0.9, 0.9]
N=37
4.4 (9.6) [0.9, 0.9, 4.7]
N=40
0.02
SD, Standard Deviation, Q1, First Quartile, Q3, Third Quartile
Supplementary Table 2 – Biomarker Summary Statistics by Stage 2/3 Acute Kidney Injury
Without Stage 2/3 AKI
All Patients (n=106)
(n=82)
Stage 2/3 AKI (n=24)
Wilcoxon
P value
Biomarker
Mean (SD) [Q1, Median, Q3]
Mean (SD) [Q1, Median, Q3]
Mean (SD) [Q1, Median, Q3]
IL-6 pre-op
4.2 (10) [0.6, 1.0, 2.8]
N=82
4.1 (11) [0.6, 0.6, 2.2]
N=65
4.3 (5.1) [0.6, 2.6, 4.9]
N=17
IL-6 day 1
128 (119) [52, 96, 165]
N=105
121 (104) [53, 91, 150]
N=81
152 (160) [47, 107, 201]
N=24
0.5
IL-6 day 3
70 (102) [19, 38, 74]
N=94
60 (90) [19, 33, 67]
N=71
101 (129) [22, 59, 109]
N=23
0.1
IL-10 pre-op
2.0 (3.4) [0.9, 0.9, 0.9]
N=82
2.1 (3.8) [0.9, 0.9, 0.9]
N=65
1.8 (1.8) [0.9, 0.9, 0.9]
N=17
0.8
IL-10 day 1
135 (144) [61, 93, 139]
N=104
128 (140) [51, 88, 139]
N=80
160 (159) [80, 95, 175]
N=24
0.3
IL-10 day 3
3.1 (7.2) [0.9, 0.9, 2.5]
N=77
1.9 (3.1) [0.9, 0.9, 0.9]
N=56
6.2 (13) [0.9, 2.6, 6.3]
N=21
Stage 2/3 AKI (atleast a doubling of serum creatinine or dialysis requirement), SD, Standard Deviation, Q1, First Quartile, Q3,
Third Quartile
0.03
0.001
Supplementary Table 3: Preoperative IL-6 and its relationship with Postoperative Tubular Injury
Biomarkers
Unadjusted
Adjusted*
2
R (p value)
R2 (p value)
NGAL Day 1
0.158 (p=0.001)
0.181 (p=0.028)
NGAL Day 2
0.706 (p=0.001)
0.210 (p=0.126)
NGAL Day 3
0.146 (p=0.006)
0.108 (p=0.18)
IL-18 Day 1
0.000 (p=0.342)
0.177 (p=0.370)
IL-18 Day 2
0.014 (p=0.378)
0.078 (p=0.345)
IL-18 Day 3
0.146 (p=0.761)
0.218 (p=0.857)
KIM-1 Day 1
0.007 (p=0.527)
0.140 (p=0.229)
KIM-1 Day 2
0.001 (p=0.780)
0.287 (p=0.802)
KIM-1 Day 3
0.001 (p=0.850)
0.279 (p=0.184)
L-FABP Day 1
0.000 (p=0.933)
0.110 (p=0.698)
L-FABP Day 2
0.035 (p=0.108)
0.069 (p=0.177)
L-FABP Day 3
0.126 (p=0.004)
0.223 (p=0.141)
Analyses were adjusted for: age, gender, race, surgical site, RACHS-1 score, CPB time